<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30369488</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>29</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Print">0301-2603</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>46</Volume>                    <Issue>10</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                    </PubDate>                </JournalIssue>                <Title>No shinkei geka. Neurological surgery</Title>                <ISOAbbreviation>No Shinkei Geka</ISOAbbreviation>            </Journal>            <ArticleTitle>[Classification of Clinical Syndromes Associated with Skull-Base Metastasis in the MR Era].</ArticleTitle>            <Pagination>                <MedlinePgn>865-873</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.11477/mf.1436203829</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Skull-base metastases frequently cause progressive ipsilateral disturbances of cranial nerves or pain, resulting in poor quality of life in patients with cancer. Magnetic resonance(MR)imaging is the method to detect skull-base metastases, which demonstrates focal lesions of low-intensity signal and enhancement on T1-weighted MR images.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">We reviewed clinical data and MR images from 127 patients with skull-base metastases diagnosed at Shizuoka Cancer Center Hospital between August 2012 and November 2017.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The most common primary site was the lung(44 patients), followed by the breast(34), colon(8), and prostate(8). The interval from diagnosis of the primary tumor to skull-base metastasis ranged from 0 to 276 months(median, 9 months). The interval was shortest with lung cancer(median, 0 month), and longest with carcinoma of the liver(median, 81 months). The most commonly affected site was the clivus(74%), followed by the petrous(35%), and the occipital condyle(18%). We classified 55 symptomatic patients into 6 clinical syndromes: orbital(18%), parasellar(7%), middle cranial fossa(24%), jugular foramen(7%), and occipital condyle(15%), described by Greenberg, and a new entity &quot;clivopetrosal&quot; syndrome presenting diplopia due to abducens palsy(20%). Of 47 patients who underwent irradiation, 29 patients(62%)achieved relief of their symptoms. Median overall survival after diagnosis of a skull-base metastasis was 7 months. Male sex and colon cancer were associated with poor prognosis.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">When a cancer patient presents with new-onset cranial nerve palsies or craniofacial pain, physicians need to identify skull-base metastases for prompt radiotherapy.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Hayashi</LastName>                    <ForeName>Nakamasa</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Neurosurgery, Shizuoka Cancer Center.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mitsuya</LastName>                    <ForeName>Koichi</ForeName>                    <Initials>K</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Deguchi</LastName>                    <ForeName>Shoichi</ForeName>                    <Initials>S</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Nakasu</LastName>                    <ForeName>Yoko</ForeName>                    <Initials>Y</Initials>                </Author>            </AuthorList>            <Language>jpn</Language>            <PublicationTypeList>                <PublicationType UI="D004740">English Abstract</PublicationType>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>Japan</Country>            <MedlineTA>No Shinkei Geka</MedlineTA>            <NlmUniqueID>0377015</NlmUniqueID>            <ISSNLinking>0301-2603</ISSNLinking>        </MedlineJournalInfo>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>30</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>30</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>30</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30369488</ArticleId>            <ArticleId IdType="pii">1436203829</ArticleId>            <ArticleId IdType="doi">10.11477/mf.1436203829</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>